Article · 5 Oct 2026
Conference abstract
Downstream processing of Monoclonal Antibodies (MAbs): Challenges and troubleshooting
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Recent advances in mammalian cell culture technology has resulted in significant increases in upstream productivity, with antibody titers >5 g/L. Such increases, leading to higher levels of product-related heterogeneous proteins like aggregates, degraded products, processing variants and cell-derived impurities such as host cell protein and DNA. Hence, the development of efficient downstream process is desired to control the impurities as well as to meet the innovator specifications. The entire purification process must be validated by demonstrating a 12 to 20 log reduction of viral load using at least four different model viruses.
Keywords
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Bioequivalence & Bioavailability.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioequivalence & Bioavailability
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Prasad Pasupuleti”